Literature DB >> 32533597

Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Edward V Nunes1, Adam Bisaga1, Evgeny Krupitsky2,3, Narinder Nangia4, Bernard L Silverman4, Sarah C Akerman4, Maria A Sullivan1,4.   

Abstract

Entities:  

Keywords:  Cognition; extended-release naltrexone; motivation; opioid blockade; opioid dependence; opioid use disorder; relapse; retention

Mesh：

Substances：

Year:  2020        PMID： 32533597      PMCID： PMC8935659          DOI： 10.1111/add.15153

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  9 in total

1.  Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

Authors:  Gary K Hulse; Hanh T T Ngo; Robert J Tait
Journal:  Biol Psychiatry       Date:  2010-05-26       Impact factor: 13.382

2.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

Review 3.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

4.  Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Authors:  Zhenhao Shi; An-Li Wang; Kanchana Jagannathan; Victoria P Fairchild; Charles P O'Brien; Anna Rose Childress; Daniel D Langleben
Journal:  J Psychiatry Neurosci       Date:  2018-02-23       Impact factor: 6.186

5.  Commentary on Nunes et al. (2020): Blocked opioid use in antagonist treatment-time for cognitive and user-centered perspectives.

Authors:  Nikolaj Kunøe
Journal:  Addiction       Date:  2019-11-22       Impact factor: 6.526

6.  Extinction as the behavioral mechanism of the naltrexone-extended release for opioid dependence: could there be an alternative explanation?

Authors:  Abhishek Ghosh; Pranshu Singh
Journal:  Addiction       Date:  2020-05-01       Impact factor: 6.526

7.  Challenges to antagonist blockade during sustained-release naltrexone treatment.

Authors:  Nikolaj Kunøe; Philipp Lobmaier; John Kåre Vederhus; Bjørg Hjerkinn; Michael Gossop; Solfrid Hegstad; Øistein Kristensen; Helge Waal
Journal:  Addiction       Date:  2010-09       Impact factor: 6.526

8.  Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Authors:  Edward V Nunes; Adam Bisaga; Evgeny Krupitsky; Narinder Nangia; Bernard L Silverman; Sarah C Akerman; Maria A Sullivan
Journal:  Addiction       Date:  2019-08-04       Impact factor: 6.526

9.  Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?

Authors:  Edward V Nunes; Jami L Rothenberg; Maria A Sullivan; Kenneth M Carpenter; Herbert D Kleber
Journal:  Am J Drug Alcohol Abuse       Date:  2006       Impact factor: 3.829
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.